Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Goodwill (2019 - 2025)

X4 Pharmaceuticals' Goodwill history spans 7 years, with the latest figure at $17.4 million for Q4 2025.

  • For Q4 2025, Goodwill changed 0.0% year-over-year to $17.4 million; the TTM value through Dec 2025 reached $17.4 million, changed 0.0%, while the annual FY2025 figure was $17.4 million, 0.0% changed from the prior year.
  • Goodwill reached $17.4 million in Q4 2025 per XFOR's latest filing, roughly flat from $17.4 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $27.1 million in Q1 2021 to a low of $17.4 million in Q4 2021.
  • Average Goodwill over 5 years is $18.8 million, with a median of $17.4 million recorded in 2021.
  • The largest YoY upside for Goodwill was 0.0% in 2021 against a maximum downside of 36.0% in 2021.
  • A 5-year view of Goodwill shows it stood at $17.4 million in 2021, then changed by 0.0% to $17.4 million in 2022, then changed by 0.0% to $17.4 million in 2023, then changed by 0.0% to $17.4 million in 2024, then changed by 0.0% to $17.4 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Goodwill are $17.4 million (Q4 2025), $17.4 million (Q3 2025), and $17.4 million (Q2 2025).